Literature DB >> 35762249

Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions.

Ayal A Aizer1, Nayan Lamba1,2, Manmeet S Ahluwalia3, Kenneth Aldape4, Adrienne Boire5, Priscilla K Brastianos6, Paul D Brown7, D Ross Camidge8, Veronica L Chiang9, Michael A Davies10, Leland S Hu11, Raymond Y Huang12, Timothy Kaufmann13, Priya Kumthekar14, Keng Lam15, Eudocia Q Lee8, Nancy U Lin8, Minesh Mehta16, Michael Parsons17, David A Reardon8, Jason Sheehan18, Riccardo Soffietti19, Hussein Tawbi10, Michael Weller20, Patrick Y Wen8.   

Abstract

Brain metastases occur commonly in patients with advanced solid malignancies. Yet, less is known about brain metastases than cancer-related entities of similar incidence. Advances in oncologic care have heightened the importance of intracranial management. Here, in this consensus review supported by the Society for Neuro-Oncology (SNO), we review the landscape of brain metastases with particular attention to management approaches and ongoing efforts with potential to shape future paradigms of care. Each coauthor carried an area of expertise within the field of brain metastases and initially composed, edited, or reviewed their specific subsection of interest. After each subsection was accordingly written, multiple drafts of the manuscript were circulated to the entire list of authors for group discussion and feedback. The hope is that the these consensus guidelines will accelerate progress in the understanding and management of patients with brain metastases, and highlight key areas in need of further exploration that will lead to dedicated trials and other research investigations designed to advance the field.
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  brain metastases; consensus; expert; guidelines; recommendations; treatment

Mesh:

Year:  2022        PMID: 35762249      PMCID: PMC9527527          DOI: 10.1093/neuonc/noac118

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  339 in total

1.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.

Authors:  Alice T Shaw; Todd M Bauer; Filippo de Marinis; Enriqueta Felip; Yasushi Goto; Geoffrey Liu; Julien Mazieres; Dong-Wan Kim; Tony Mok; Anna Polli; Holger Thurm; Anna M Calella; Gerson Peltz; Benjamin J Solomon
Journal:  N Engl J Med       Date:  2020-11-19       Impact factor: 91.245

Review 2.  Cerebral radiation necrosis.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Neurologist       Date:  2003-07       Impact factor: 1.398

3.  Diffusion-weighted MRI features of brain abscess and cystic or necrotic brain tumors: comparison with conventional MRI.

Authors:  Shih Chin Chang; Ping Hong Lai; Wei Liang Chen; Hsu Huei Weng; Jih Tsun Ho; Jyh Seng Wang; Chuan Yu Chang; Huay Ben Pan; Chien Fang Yang
Journal:  Clin Imaging       Date:  2002 Jul-Aug       Impact factor: 1.605

4.  Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.

Authors:  Jack M Qian; Allison M Martin; Kate Martin; Lubna Hammoudeh; Paul J Catalano; F Stephen Hodi; Daniel N Cagney; Daphne A Haas-Kogan; Jonathan D Schoenfeld; Ayal A Aizer
Journal:  Cancer       Date:  2020-09-14       Impact factor: 6.860

5.  Adrenal suppression after short-term corticosteroid therapy.

Authors:  R J Spiegel; R A Vigersky; A I Oliff; C K Echelberger; J Bruton; D G Poplack
Journal:  Lancet       Date:  1979-03-24       Impact factor: 79.321

Review 6.  Brain metastasis.

Authors:  Adrienne Boire; Priscilla K Brastianos; Livia Garzia; Manuel Valiente
Journal:  Nat Rev Cancer       Date:  2019-11-28       Impact factor: 60.716

7.  AKT1 Activation Promotes Development of Melanoma Metastases.

Authors:  Joseph H Cho; James P Robinson; Rowan A Arave; William J Burnett; David A Kircher; Guo Chen; Michael A Davies; Allie H Grossmann; Matthew W VanBrocklin; Martin McMahon; Sheri L Holmen
Journal:  Cell Rep       Date:  2015-10-22       Impact factor: 9.423

8.  A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy.

Authors:  Jerome M Butler; L Douglas Case; James Atkins; Bart Frizzell; George Sanders; Patricia Griffin; Glenn Lesser; Kevin McMullen; Richard McQuellon; Michelle Naughton; Stephen Rapp; Volker Stieber; Edward G Shaw
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-09-14       Impact factor: 7.038

9.  Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study.

Authors:  Daniel N Cagney; Allison M Martin; Paul J Catalano; Amanda J Redig; Nancy U Lin; Eudocia Q Lee; Patrick Y Wen; Ian F Dunn; Wenya Linda Bi; Stephanie E Weiss; Daphne A Haas-Kogan; Brian M Alexander; Ayal A Aizer
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

10.  Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.

Authors:  Jose Pablo Leone; Kyrre E Emblem; Michelle Weitz; Rebecca S Gelman; Bryan P Schneider; Rachel A Freedman; Jerry Younger; Marco C Pinho; A Gregory Sorensen; Elizabeth R Gerstner; Gordon Harris; Ian E Krop; Daniel Morganstern; Jessica Sohl; Jiani Hu; Elizabeth Kasparian; Eric P Winer; Nancy U Lin
Journal:  Breast Cancer Res       Date:  2020-11-30       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.